The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.
Site Search
In August, CF Advocates visited their representatives in the U.S. House as part of the CF Foundation's first ever national summer advocacy campaign, “House Calls.”
William Skach, MD, Chief Scientific Officer, will retire from the CF Foundation this summer.
Legislation introduced today will help more people with cystic fibrosis, and other rare diseases, participate in clinical trials without fear of losing important benefits or health coverage. The bill is sponsored by a bipartisan group of senators and legislators.
William Elder, Jr., a medical student with cystic fibrosis and long-time advocate for the CF community, has been invited to sit with First Lady Michelle Obama at tonight's State of the Union address. The White House invitation highlights the momentum and progress toward finding a cure for this devastating disease.